Table 1 Demographics and disease characteristics of the patients included in the PRFs

Age, years

 50–54

9 (5)

20 (10)

 55–59

41 (21)

42 (21)

 60–64

51 (26)

51 (26)

 65–69

28 (14)

35 (18)

 70–74

41 (21)

30 (15)

 75–79

19 (10)

12 (6)

 ≥ 80

11 (6)

10 (5)

Time since diagnosis

 < 7 months

55 (28)

52 (26)

 7–12 months

58 (29)

45 (23)

 > 12 months

87 (44)

103 (52)

Comorbidities

 Hypertension

133 (67)

162 (81)

 Diabetes

92 (46)

98 (49)

 Dyslipidemia

91 (46)

65 (33)

 Overweight/obesity

73 (37)

78 (39)

 Cardiovascular disease

55 (28)

40 (20)

 Sexual dysfunction

53 (27)

69 (35)

 Non-prostatic malignancy

4 (2)

1 (0.5)

 Neurological condition

4 (2)

0 (0)

 No comorbidities

18 (9)

17 (9)

Type of sexual dysfunction

N = 53

N = 69

 Erectile dysfunction

46 (87)

63 (91)

 Ejaculatory dysfunction

5 (9)

8 (12)

 Negative impact on libido/sexual desire

4 (8)

16 (23)

 Negative impact on global sexual function

5 (9)

10 (15)

Risk categorization when 5ARI was initiated

N = 200

N = 200

 At risk of progression

163 (82)

176 (88)

 Not at risk of progression

37 (19)

24 (12)

Symptom severity based on IPSS

N = 116

N = 51

 Severe

45 (39)

13 (26)

 Moderate

68 (59)

35 (69)

 Mild

3 (3)

3 (6)

Symptom severity per clinical assessment

N = 81

N = 145

 Severe

30 (37)

41 (28)

 Moderate

49 (61)

94 (65)

 Mild

2 (3)

10 (7)